Literature DB >> 21803762

Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas.

Lars Fischer1, Michael Hummel, Agnieszka Korfel, Dido Lenze, Korrina Joehrens, Eckhard Thiel.   

Abstract

Most primary CNS lymphomas (PCNSL) are diffuse large B-cell lymphomas (DLBCL). However, clinical behavior and prognosis differ considerably from those for nodal DLBCL (nDLBCL), and their pathogenesis is still not fully understood. Micro-RNAs (miRNAs) have been associated with cancer development and progression. We investigated a large miRNA panel for differential expression in PCNSL and nDLBCL, to determine new mechanisms potentially involved in PCNSL pathogenesis. Using paraffin-embedded biopsy specimens from 21 HIV-negative patients with newly diagnosed PCNSL (n = 11) and nDLBCL (n= 10), we measured the expression of 365 miRNA species by quantitative real-time PCR using low-density PCR arrays. We found that 18 miRNAs were differentially expressed: median expression levels of 13 miRNAs were 2.1-13.1 times higher in PCNSL, and median expression levels of 5 miRNAs were 2.6-3.3 times higher in nDLBCL. MiRNAs upregulated in PCNSL were associated with the Myc pathway (miR-17-5p, miR-20a, miR-9), with blocking of terminal B-cell differentiation (miR-9, miR-30b/c), or with upregulation by inflammatory cytokines (miR-155). Putative tumor-suppressor miRNAs (miR-199a, miR-214, miR-193b, miR-145) were downregulated in PCNSL. There was no overlap of miRNAs dysregulated in PCNSL with those differentially expressed between immunohistologically defined germinal center B cell-like (GCB) and non-GCB types or, apart from miR-9, with miRNAs known to be overexpressed in human brain. We conclude that PCNSL exhibits a distinct pattern of miRNA expression compared with nDLBCL. This argues for the involvement of different molecular mechanisms in the pathogenesis of these two lymphoma types.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21803762      PMCID: PMC3177663          DOI: 10.1093/neuonc/nor107

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  57 in total

1.  Identification and characterization of human BIC, a gene on chromosome 21 that encodes a noncoding RNA.

Authors:  W Tam
Journal:  Gene       Date:  2001-08-22       Impact factor: 3.688

2.  Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals.

Authors:  Chung-Che Chang; Bal Kampalath; Christopher Schultz; Ellen Bunyi-Teopengco; Brent Logan; Camellia Eshoa; Ayse P Dincer; Sherrie L Perkins
Journal:  Arch Pathol Lab Med       Date:  2003-02       Impact factor: 5.534

3.  High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.

Authors:  Eckhard Thiel; Agnieszka Korfel; Peter Martus; Lothar Kanz; Frank Griesinger; Michael Rauch; Alexander Röth; Bernd Hertenstein; Theda von Toll; Thomas Hundsberger; Hans-Günther Mergenthaler; Malte Leithäuser; Tobias Birnbaum; Lars Fischer; Kristoph Jahnke; Ulrich Herrlinger; Ludwig Plasswilm; Thomas Nägele; Torsten Pietsch; Michael Bamberg; Michael Weller
Journal:  Lancet Oncol       Date:  2010-10-20       Impact factor: 41.316

4.  Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10.

Authors:  Lisa M DeAngelis; Wendy Seiferheld; S Clifford Schold; Barbara Fisher; Christopher J Schultz
Journal:  J Clin Oncol       Date:  2002-12-15       Impact factor: 44.544

5.  Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system.

Authors:  Alexander Baraniskin; Jan Kuhnhenn; Uwe Schlegel; Andrew Chan; Martina Deckert; Ralf Gold; Abdelouahid Maghnouj; Hannah Zöllner; Anke Reinacher-Schick; Wolff Schmiegel; Stephan A Hahn; Roland Schroers
Journal:  Blood       Date:  2011-01-03       Impact factor: 22.113

6.  Repression of c-myc is necessary but not sufficient for terminal differentiation of B lymphocytes in vitro.

Authors:  K I Lin; Y Lin; K Calame
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

7.  miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis.

Authors:  Li Ma; Jennifer Young; Harsha Prabhala; Elizabeth Pan; Pieter Mestdagh; Daniel Muth; Julie Teruya-Feldstein; Ferenc Reinhardt; Tamer T Onder; Scott Valastyan; Frank Westermann; Frank Speleman; Jo Vandesompele; Robert A Weinberg
Journal:  Nat Cell Biol       Date:  2010-02-21       Impact factor: 28.824

Review 8.  MicroRNAs in cancer: small molecules with a huge impact.

Authors:  Marilena V Iorio; Carlo M Croce
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

9.  Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer.

Authors:  X-F Li; P-J Yan; Z-M Shao
Journal:  Oncogene       Date:  2009-08-24       Impact factor: 9.867

10.  miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer.

Authors:  Hanna E Rauhala; Sanni E Jalava; Jarkko Isotalo; Hazel Bracken; Saara Lehmusvaara; Teuvo L J Tammela; Hannu Oja; Tapio Visakorpi
Journal:  Int J Cancer       Date:  2010-09-01       Impact factor: 7.396

View more
  42 in total

Review 1.  New approaches in primary central nervous system lymphoma.

Authors:  Eleanor Fraser; Katherine Gruenberg; James L Rubenstein
Journal:  Chin Clin Oncol       Date:  2015-03

Review 2.  Advances in Primary Central Nervous System Lymphoma.

Authors:  Lauren B Patrick; Nimish A Mohile
Journal:  Curr Oncol Rep       Date:  2015-12       Impact factor: 5.075

3.  Serum microRNAs in HIV-infected individuals as pre-diagnosis biomarkers for AIDS-NHL.

Authors:  Dharma R Thapa; Shehnaz K Hussain; Wen-Ching Tran; Gypsyamber Dʼsouza; Jay H Bream; Chad J Achenback; Velpandi Ayyavoo; Roger Detels; Otoniel Martínez-Maza
Journal:  J Acquir Immune Defic Syndr       Date:  2014-06-01       Impact factor: 3.731

4.  Prognostic impact of MYC protein expression in central nervous system diffuse large B-cell lymphoma: comparison with MYC rearrangement and MYC mRNA expression.

Authors:  Seung-Myoung Son; Sang-Yun Ha; Hae-Yong Yoo; Dongryul Oh; Seok-Jin Kim; Won-Seog Kim; Young-Hyeh Ko
Journal:  Mod Pathol       Date:  2016-09-30       Impact factor: 7.842

Review 5.  Biology of CNS lymphoma and the potential of novel agents.

Authors:  James L Rubenstein
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 6.  The Challenge of Primary Central Nervous System Lymphoma.

Authors:  Julia Carnevale; James L Rubenstein
Journal:  Hematol Oncol Clin North Am       Date:  2016-12       Impact factor: 3.722

7.  MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS.

Authors:  Alexander Baraniskin; Monika Chomiak; Guido Ahle; Thomas Gress; Malte Buchholz; Michael Turewicz; Martin Eisenacher; Michelle Margold; Uwe Schlegel; Wolff Schmiegel; Stephan Hahn; Roland Schroers
Journal:  J Neurooncol       Date:  2018-01-11       Impact factor: 4.130

8.  MicroRNA 9-3p targets β1 integrin to sensitize claudin-low breast cancer cells to MEK inhibition.

Authors:  Jon S Zawistowski; Kazuhiro Nakamura; Joel S Parker; Deborah A Granger; Brian T Golitz; Gary L Johnson
Journal:  Mol Cell Biol       Date:  2013-03-25       Impact factor: 4.272

9.  How I treat CNS lymphomas.

Authors:  James L Rubenstein; Neel K Gupta; Gabriel N Mannis; Amanda K Lamarre; Patrick Treseler
Journal:  Blood       Date:  2013-08-20       Impact factor: 22.113

Review 10.  Role of microRNAs in primary central nervous system lymphomas.

Authors:  Xin Yu; Zheng Li; Jianxiong Shen; Matthew T V Chan; William Ka Kei Wu
Journal:  Cell Prolif       Date:  2016-03-16       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.